Connective Tissue Diseases (Connective Tissue Disease)
1621
relevant articles (42 outcomes,
150 trials/studies)
found for this Disease
Description:
A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
Also Known As:
Connective Tissue Disease; Disease, Connective Tissue; Diseases, Connective Tissue
Relationship Network
Disease Context: Research Results
Related Diseases
Drugs and Biologics
Drugs and Important Biological Agents (IBA) related to Connective Tissue Diseases:
| 1. | bosentan (Tracleer)FDA Link
|
| 2. | AntibodiesIBA
|
| 3. | Antinuclear AntibodiesIBA
|
| 4. | sildenafil (Viagra)FDA Link
|
| 5. | Etidronic Acid (HEDP)FDA LinkGeneric
|
| 6. | TBC 11251 (sitaxsentan)IBA
11/01/2004
- " In its first randomised, placebo-controlled study, Sitaxsentan to Relieve Impaired Exercise-1 (STRIDE-1), sitaxsentan improved exercise capacity assessed by 6 min walk, New York Heart Association functional class, cardiac index and pulmonary vascular resistance in New York Heart Association class II, III and IV patients with idiopathic PAH, PAH related to connective tissue disease or PAH related to congenital heart disease" 05/01/2008
- " Is sitaxsentan a good therapeutic option for pulmonary arterial hypertension associated with connective tissue disease?" 01/01/2007
- " METHODS: Forty-eight patients with idiopathic PAH or PAH associated with connective-tissue disease or congenital heart disease were randomized (double-blind) to a single daily dose of either 50 mg or 100 mg sitaxsentan" 11/01/2005
- " In its first randomized, placebo-controlled study, sitaxsentan improved exercise capacity assessed by the 6-min walk test, New York Heart Association functional class, cardiac index and pulmonary vascular resistance in New York Heart Association Class II, III and IV patients with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension related to connective tissue disease or congenital heart disease" 02/15/2004
- " Patients with pulmonary arterial hypertension that was idiopathic, related to connective tissue disease or congenital heart disease, were randomized to receive placebo (n = 60), sitaxsentan 100 mg (n = 55), or sitaxsentan 300 mg (n = 63) orally once daily for 12 weeks"
Get all the results and reference details, order at left...
|
| 7. | Cyclophosphamide (Cytoxan)FDA Link
|
| 8. | Trimethoprim-Sulfamethoxazole Combination (Co-Trimoxazole)FDA LinkGeneric
|